Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase iii Himalaya study

dc.contributor.author	Vogel, A.
dc.contributor.author	Chan, S. L.
dc.contributor.author	Furuse, J.
dc.contributor.author	Tak, W. Y.
dc.contributor.author	Masi, G.
dc.contributor.author	Varela Calvo, María
dc.contributor.author	Kim, J. H.
dc.contributor.author	Tanasanvimon, S.
dc.contributor.author	Reig Monzon, M. E.
dc.contributor.author	Dayyani, F.
dc.contributor.author	Makowsky, M.
dc.contributor.author	Marcovitz, M.
dc.contributor.author	Negro, A.
dc.contributor.author	Abou-Alfa, G. K.
dc.date.accessioned	2023-05-18T08:21:59Z
dc.date.available	2023-05-18T08:21:59Z
dc.date.issued	2022
dc.identifier.issn	0923-7534
dc.identifier.uri	http://hdl.handle.net/10651/68157
dc.description	European Society for Medical Oncology, ESMO Asia Congress (2022. Singapore)
dc.language.iso	eng
dc.relation.ispartof	Annals of Oncology
dc.rights	© 2022 Elsevier
dc.source	WOS:000897943700081
dc.title	Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase iii Himalaya study
dc.type	conference output	spa
dc.identifier.doi	10.1016/j.annonc.2022.10.115
dc.relation.publisherversion	http://dx.doi.org/10.1016/j.annonc.2022.10.115

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.